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Age-related macular degeneration (AMD) is a complex multifactorial disease that affects the central region of the
retina. AMD is clinically heterogeneous, leading to geographic atrophy (GA) and/or choroidal neovascularization
(CNV) at advanced stages. Considerable data exists in support of a genetic predisposition for AMD. Recent linkage
studies have provided evidence in favor of several AMD susceptibility loci. We have performed a high-resolution
(5-cM) genome scan of 412 affected relative pairs that were enriched for late-stage disease (GA and/or CNV).
Nonparametric linkage analysis was performed using two different diagnostic criteria and also by dividing the
affected individuals according to GA or CNV phenotype. Our results demonstrate evidence of linkage in regions
that were suggested in at least one previous study at chromosomes 1q (236–240 cM in the Marshﬁeld genetic map),
5p (40–50 cM), and 9q (111 cM). Multipoint analysis of affected relatives with CNV provided evidence of additional
susceptibility loci on chromosomes 2p (10 cM) and 22q (25 cM). A recently identiﬁed Gln5345Arg change in
HEMICENTIN-1 on chromosome 1q25 was not detected in 274 affected members in the restricted group with
AMD, 346 additional patients with AMD, and 237 unaffected controls. Our results consolidate the chromosomal
locations of several AMD susceptibility loci and, together with previous reports, should facilitate the search for
disease-associated sequence variants.
Introduction
Age-relatedmacular degeneration (AMD [MIM603075])
is a complex, multifactorial neurodegenerative disease
that leads to visual impairment and results in half of all
cases of legal blindness in Western populations 165 years
of age (Klein et al. 1992; Vingerling et al. 1995; Bird
2003). In the United States, 11.6 million individuals are
affected with late-stage AMD, and 30% of individuals
175 years of age show some signs of disease (Prevent
Blindness America and National Eye Institute 2002). A
dramatic increase in the size of the aging population
makes AMD a signiﬁcant public health problem and a
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major focus of research efforts (National Advisory Eye
Council 1998). There is currently no cure, and the
impact of speciﬁc interventions is limited.
AMD is a progressive disease encompassing a broad
spectrum of clinical ﬁndings that primarily affect the
central (macular) region of the retina (Bressler et al.
1988; Ambati et al. 2003). Early manifestations of the
disease include the appearance of drusen, accumulations
of acellular debris in the basement membrane of the
retinal pigment epithelium (RPE), and pigmentary ab-
normalities in the macular region. Although small dru-
sen are commonly observed in the aging macula, the
presence of large drusen is considered diagnostic for
AMD (Bird et al. 1995). Late stages of AMD are typ-
ically grouped in two forms: (1) a “dry” form associated
with the loss of RPE and photoreceptors and diminished
retinal function, known as “geographic atrophy” (GA);
and (2) a “wet” exudative form, which is associated
with the formation of choroidal neovascularization
(CNV), leading to sub-RPE or subretinal hemorrhage,
subretinal ﬂuid, macular edema, and, eventually, ﬁbrotic
scarring. Although GA and CNV together account for
only 10% of patients with AMD (Smith et al. 2001),
the two are responsible for most cases of associated
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blindness. At present, it is unclear whether these forms
represent different clinical entities with distinct genetic
etiology or stages in a single disease continuum (Gorin
et al. 1999). During the course of disease, ophthalmic
ﬁndings in a single individual can include multiple clin-
ical pathologies. Large drusen and pigmentary changes
typically precede both GA and CNV, and a single af-
fected individual may exhibit both forms of the late-
stage disease (Green 1999; Ambati et al. 2003). Oxi-
dative stress and immune-mediated processes are
believed to contribute to AMD pathogenesis (Cai et al.
2000; Hageman et al. 2001; Crabb et al. 2002; Johnson
et al. 2002; Ambati et al. 2003); however, precise mo-
lecular events have not yet been elucidated.
Epidemiological studies have implicated interaction
of environmental and genetic factors in AMD patho-
genesis. Although a number of lifestyle factors (e.g.,
alcohol consumption, light exposure, diet, smoking)
may inﬂuence disease manifestation (Hirvela et al. 1996;
Klein et al. 1997; Smith et al. 2001), the strongest risk
factors identiﬁed to date are age and family history
(Evans 2001). Aging itself appears to be a multifactorial
and genetically determined process (Hekimi and Guar-
ente 2003), and it inﬂuences expression of several genes
in the retina (Yoshida et al. 2002; S. Yoshida, S. Za-
reparsi, and A. Swaroop, unpublished data). Population
studies have suggested familial aggregation of AMD and
genetic predisposition to disease pathogenesis (Seddon
et al. 1997; Klaver et al. 1998; Gorin et al. 1999). The
phenotypic similarities between monogenic early-onset
macular disease and AMD prompted several association
studies; however, the genes responsible for monogenic
diseases do not appear to make a signiﬁcant contribu-
tion to AMD (Stone et al. 2001). To date, only allelic
variations in apolipoprotein-E (APOE) and possibly the
retinal ATP-binding cassette transporter gene ABCR
have been associated with susceptibility to AMD (Al-
likmets et al. 2000; Schmidt et al. 2002).
The ﬁrst tentative localization of a genetic locus for
AMD (ARMD1) on chromosome 1q25-31 was pro-
vided by linkage analysis of data from a family with a
predominantly dry form of disease that exhibited a
dominant mode of inheritance (Klein et al. 1998).
Thereafter, a genome scan of affected sib pairs provided
suggestive evidence for AMD susceptibility loci on chro-
mosomes 5, 9, and 10 (Weeks et al. 2000). A follow-
up genome scan, including some of the same samples,
however, indicated linkage to 1q31 and 17q25 (Weeks
et al. 2001). Recently, three independent genomewide
scans have provided evidence for a number of suggestive
AMD susceptibility loci, which include the locus at 1q
(Majewski et al. 2003; Schick et al. 2003; Seddon et al.
2003). Recently, a Gln5345Arg change in the HEMI-
CENTIN-1 gene was reported to be associated with the
disease in the original AMD family that exhibited link-
age to chromosome 1q25-31 (Schultz et al. 2003).
The power of affected relative pair studies depends
on the increased risk of disease to individuals who share
a particular locus identical by descent (IBD) with an
affected relative (Risch 1990). As prevalence increases,
the maximum possible increase in risk attributable to
any one locus decreases. The late-stage AMD pheno-
types (GA and CNV) are rarer and may occur in in-
dividuals who are genetically more susceptible. We hy-
pothesized that the individuals with late-stage AMD
would typically carry a heavier load of genetic suscep-
tibility factors than other patients with AMD and thus
would be well suited for genetic investigations. Consis-
tent with this hypothesis, studies by Klaver et al. (1998)
show that ﬁrst-degree relatives of individuals with late-
stage AMD have substantially increased risk and earlier
onset of maculopathy than the general population.
Here, we report the results of a 5-cM genomewide link-
age study in families enriched for late-stage AMD, with
the majority of individuals affected by GA and/or CNV.
In addition to the ARMD1 locus, our results demon-
strate evidence of linkage on chromosomes 2p (10 cM
on theMarshﬁeld genetic map), 5p (40–50 cM), 9q (111
cM), and 22q (25 cM).
Material and Methods
Family Recruitment and Selection
Families with AMD were primarily ascertained and
recruited from the clinical practice at the Kellogg Eye
Center, University of Michigan Hospitals. Since the Ret-
ina Clinic serves as a tertiary health care center for the
State of Michigan and the surrounding Great Lakes re-
gion, the patient population is biased toward late-stage
AMD (69% of the affected individuals in our study have
GA and/or CNV). The patient population used for ge-
notyping in this study is white and primarily of Western
European ancestry, reﬂecting the genetic constitution of
the Great Lakes region. Ophthalmic records for current
and previous eye examinations, fundus photographs,
and ﬂuorescein angiograms were obtained for all pro-
bands and family members. All records and ophthalmic
documentation were scored for the presence of AMD
clinical ﬁndings in each eye and were updated every 1–
2 years. The recruitment and research protocols were
reviewed and approved by the University of Michigan
institutional review board, and informed consent was
obtained from all study participants.
Disease Classiﬁcation
Fundus ﬁndings in each eye were classiﬁed on the basis
of a standardized set of diagnostic criteria established
by the International Age-Related Maculopathy Epide-
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miological Study (Bird et al. 1995). The following in-
dividuals were excluded from the study: patients with a
history of severe macular disease or vision loss before
40 years of age; others with signs of a juvenile macular
or retinal degeneration (such as Stargardt or Best disease)
or macular damage resulting from ocular trauma, retinal
detachment, high myopia, chorioretinal infective or in-
ﬂammatory processes, or choroidal dystrophy; and those
with inadequate documentation.
For the genetic studies reported here, macular ﬁndings
were scored in each individual by use of two clinical
grading systems: a restricted deﬁnition (R-AMD) and a
broad description (B-AMD) of AMD. For an individual
to be graded as affected in the R-AMD category, the
clinical ﬁndings had to include: (1) CNV and/or GA and/
or large macular drusen in at least one eye with clearly
documented coarse RPE changes and/or macular drusen
in the fellow eye or (2) at least 3 years of medical records
from a collaborating ophthalmologist documenting a
history of atrophic AMD bilaterally or small macular
drusen and coarse RPE changes bilaterally. In the B-
AMD analysis, the requirements for the quality, consis-
tency, and length of the ophthalmic documentation were
relaxed. This double-grading system minimized the am-
biguities in distinguishing macular pathology caused by
AMD or resulting from the natural aging process, ac-
commodated variations in the quality of clinical docu-
mentation, which varied because of enrollment pro-
cedures, and allowed the inclusion of individuals who
had not been directly evaluated by a collaborating oph-
thalmologist. Clinical documentation for 331 affected
individuals (under both the broad and restrictedmodels)
spanned, on average, 5.3 years.
In total, our sample included 1242 informative af-
fected relative pairs (including 179 sibling pairs, 40
cousin pairs, 20 avuncular pairs, 3 half-sibling pairs, and
additional more distant relatives) under the restricted
phenotype deﬁnition (R-AMD), and it included 1412
affected relative pairs (including 255 sibling pairs, 116
cousin pairs, 36 avuncular pairs, and 5 half-sibling pairs)
under the broader classiﬁcation scheme (B-AMD).
Sample Preparation
DNA from all study participants was extracted from
10 ml of EDTA-treated blood by use of the Wizard Ge-
nomic DNA Puriﬁcation Kit (Promega) (Miller et al.
1988). In families with only two affected individuals, we
collected DNA samples for genotyping from unaffected
ﬁrst-degree relatives (parents and siblings), whenever
possible. Inclusion of three genotyped individuals per
family improved our ability to detect genotyping errors
and estimate allele sharing.
Genome Scan
A high-resolution 5-cM genomewide screen was per-
formed at the Marshﬁeld Clinic Research Foundation
(Marshﬁeld, WI). This higher marker density enhanced
our ability to detect linkage and assisted in detecting
misspeciﬁed relationships and genotyping errors in this
population with AMD, in which parental genotypes
were not available for most of the families. A total of
427 samples were screened using 734 autosomal and 39
X-linked microsatellite markers. The marker set was
composed primarily of trinucleotide and tetranucleotide
repeat markers and was based on the Marshﬁeld Ge-
netics screening sets 12 and 52. For autosomes, the av-
erage distance between consecutive markers was 4.71
cM (2.53 cM). The maximum intermarker distance
was 14.3 cM, and 29 pairs of consecutive markers were
separated by 10 cM. We collected a total of 306,134
genotypes, which corresponded to an overall genotyping
success rate of 93%. Average heterozygosity was 72%
for autosomal markers and 68% for markers on the X
chromosome (in females).
Error Checking
In the absence of parental genotypes, deviations from
Hardy-Weinberg equilibrium (HWE) can bias the evi-
dence for linkage. We checked HWE for all markers by
ﬁrst selecting one individual from each pedigree, col-
lapsing rare alleles so that expected counts were more
than three for all genotype classes, and, ﬁnally, con-
ducting a x2 test (Weir 1990). For markers on the X
chromosome, we considered only female individuals.We
identiﬁed two markers (AAT035 and GAAA1C11) with
signiﬁcant (P ! .0001) deviations from HWE and ex-
cluded these markers from further analysis. Familial re-
lationships were veriﬁed using the GRR (Abecasis et al.
2001b) and RELPAIR (Epstein et al. 2000) programs.
Nine families showed pedigree errors. In four of these
families, individuals reported to be full siblings were al-
most certainly half siblings. In another family, an indi-
vidual reported to be a full sibling appeared to be un-
related. Parents’ sex was misspeciﬁed in two families.
Finally, in two other families we identiﬁed two pairs of
identical twins, allowing us to estimate the error rate in
our experiments. One twin pair was genotyped at 700
markers and another at 754 markers. In total, we ob-
served one discrepancy between twin genotypes, for an
overall discrepancy rate of !1/1,000. All these pedigree
errors were corrected prior to linkage analysis. We also
used the MERLIN program (Abecasis et al. 2002) to
check for Mendelian inconsistencies and to identify ge-
notypes associated with an excessive number of recom-
bination events.
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Figure 1 Nonparametric linkage analysis at each marker by use of the NPLALL statistics (Whittemore and Halpern 1994). LOD scores
(Kong and Cox 1997) for six disease subtypes were plotted for every marker location. The solid symbols denote the strict trait deﬁnition, and
the empty ones denote the broad trait deﬁnition. The blue symbols indicate AMD, the red symbols indicate GA, and the green symbols indicate
CNV.
Genetic Map Validation
During the course of the analyses, we compared the
genetic and physical maps for the microsatellite markers
used in our study. We identiﬁed a few previously doc-
umented discrepancies (DeWan et al. 2002). For every
set of ﬁve adjacent markers, we calculated the likelihood
of the observed genotypes, assuming (1) the ordering
implied by the genetic map; (2) the ordering implied by
the physical map; and (3) that one of the markers was
unlinked. The genetic map was well supported for nearly
all markers, but we identiﬁed three markers (TAT024,
GATA43F06, and GATA72A06) for which relatively
large log-likelihood ratios supported a different order
(155.637, 139.796, and 16.558, respectively). These
markers were not considered in subsequent analyses.
Nonparametric Linkage Analysis
We performed genomewide, nonparametric linkage
analyses using the SALL statistic (Whittemore and Hal-
pern 1994), as recommended by Sengul et al. (2001).
This statistic combines information from all affected in-
dividuals in a pedigree and can detect regions of excess
IBD sharing. We conducted single-point and multipoint
analyses with the MERLIN program (Abecasis et al.
2002). For X-chromosome analyses, we used MINX
(Merlin-In-X), a modiﬁed version of MERLIN. Since we
cannot specify an accurate genetic model for a complex
disease such as AMD, we report only nonparametric
LOD scores. It is our experience that, although para-
metric LOD scores for some models would be slightly
higher for each of the identiﬁed loci, a similar set of
susceptibility loci would be discovered.
Empirical Signiﬁcance Levels
We calculated genomewide signiﬁcance levels by use
of 100 (for single-point analysis) or 25 (for multipoint
analysis) gene-dropping simulations. Computational
constraints precluded additional multipoint simulations:
our largest pedigree included a total of 30 individuals
(including 10 affected), and performing analysis at
equally spaced 1-cM intervals throughout the genome
required ∼4 d. In each simulation, we retained the orig-
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Table 2
Peak Single-Point LOD Scores
CHROMOSOME
AND MARKER
LOCATION
(CM)
PEAK LOD FOR PHENOTYPE
B-AMD R-AMD B-GA R-GA B-CNV R-CNV
1:
GATA51H01 205 1.55 (.004) … … … … …
2:
AGAT021 266 … … … … 1.84 (.002) 1.73 (.002)
5:
GATA12A08 40 2.08 (.001) … … … … …
GATA7C06 45 … … 1.77 (.002) 1.73 (.002) … …
AAT255 130 … … … … 1.97 (.001) 1.89 (.002)
7:
TTTA001 125 1.77 (.002) 2.06 (.001) … … … …
AGAT133 126 1.70 (.003) … … … … …
9:
AGAT142 34 … … … … 1.91 (.0015) 1.84 (.002)
GGAA22E01 11 … 1.78 (.002) … … … …
11:
GATA48E02 21 … … … … 1.71 (.003) …
14:
GATA90G11 51 … … 1.52 (.004) … … …
15:
GATA151F03N 60 … … … … 1.55 (.004) 1.55 (.004)
17:
GATA25A04 62 … … 1.53 (.004) 1.66 (.003) … …
ATC6A06N 67 … … … … 2.12 (.0009) 1.89 (.002)
19:
GATA146H09 11 1.63 (.003) … … … … …
21:
GATA70B08 58 1.53 (.004) 1.56 (.004) … … … …
22:
AGAT055Z 25 … … … … 2.55 (.0003) 2.59 (.0003)
X:
TTTA062 181 … … … … 1.91 (.002) 1.82 (.002)
NOTE.—Nonparametric linkage analysis was performed using the SALL statistic (Whittemore and Halpern 1994). The
table lists all markers with a LOD score (Kong and Cox 1997) 11.5 in single-point analyses, with the peak P value in
parentheses. Marker locations are given according to the Marshﬁeld genetic map.
inal phenotypes and generated a new data set with the
same allele frequencies, marker spacings, phenotypes,
and missing-data patterns. Any evidence for linkage in
this simulated data is due to chance. We analyzed each
replicate and recorded the highest peak for each chro-
mosome to evaluate the false-positive rate. These sim-
ulations allowed us to account for uneven marker spac-
ing and informativeness, as well as the diversity of family
structures in our study, and to calculate the probability
of observing multiple linkage peaks of a certain height.
(See the work of Kruglyak and Daly [1998] for a dis-
cussion of the utility of empirical signiﬁcance levels in
linkage analysis.)
Correlations to Age and between Different Linkage
Signals
We calculated each family’s contribution to the overall
nonparametric LOD score. To evaluate whether the loci
we identiﬁed are associated with an earlier age at onset,
we calculated Pearson’s correlation coefﬁcient between
the LOD score and the average age at diagnosis of af-
fected individuals in each family. We used a one-tailed
test to examine whether linkage was stronger in families
with a lower mean age at diagnosis. To evaluate whether
there was evidence for interaction between different loci,
we calculated Pearson’s correlation coefﬁcient between
the LOD score contributions of each family to different
pairs of loci. When testing for interaction, we used a
two-sided test, similar to the analysis performed by Ma-
jewski et al. (2003).
Analysis of HEMICENTIN-1
We screened all affected members in the R-AMD group
( ), 346 additional patients with AMD, and 237np 274
unaffected controls for the Gln5345Argmutation. A 225-
bp region of exon 104 of theHEMICENTIN-1 gene was
ampliﬁed by PCR by use of the following primers: F-5′-
CATTAATGAATGTGAACAAGTGC-3′ and R-5′-TGT-
CTGTAATGCTGTTGAGGTTG-3′. The ampliﬁed prod-
uct was sequenced at the University of Michigan DNA
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Sequencing Core, and the chromatogramswere readusing
the Chromas software, version 1.45 (Grifﬁth University,
School of Health Science).
Results
The characteristics of the families with AMD that were
genotyped in our study, under both the restricted and
broad models of disease, are summarized in table 1.Note
that all of the families in our study include at least one
individual who satisﬁes the strict deﬁnition of AMD, and
82% of families (93/113) include two such affected in-
dividuals (table 1). In addition, 93% of all of the families
in our study include one genotyped individual who was
diagnosed with bilateral AMD and has the late-stage
disease (GA or CNV). Broadening the deﬁnition of dis-
ease did not signiﬁcantly alter the characteristics of the
study population (table 1). Under both deﬁnitions, the
average age, sex, and percentage of individuals with late-
stage forms of disease were roughly equivalent. The
overall family structures were also similar: in the R-
AMD model, 84% of the families were composed of
three or fewer affected individuals, whereas in the B-
AMD model, the families were slightly larger, and 78%
had three or fewer affected individuals (table 1). Under
both models, 195% reported a family history that in-
cluded at least one affected ﬁrst-degree relative, and
155% reported a family history with at least three af-
fected individuals in two generations of the family.
In the R-AMD analysis, 274 individuals were ana-
lyzed; the probands and their family members were pre-
dominantly affected with late-stage forms of AMD (ta-
ble 1), and 75% of the family pairs were composed of
siblings. The B-AMD clinical model added 57 affected
individuals and 22 informative families (table 1). Al-
though the bias toward late-stage forms (GA and/or
CNV) was maintained in this expanded study popula-
tion (58%–70% of all affected individuals), the B-AMD
model included nearly double the number of individuals
with other forms of AMD.
Single-Point Results
Our initial single-point analyses identiﬁed several link-
age signals at a LOD score (Kong and Cox 1997) thresh-
old of 1.5 (summarized in ﬁg. 1 and in table 2). We ob-
served the strongest evidence for linkage ( ;LODp 2.59
asymptotic ) among patients whomet the strictPp .0003
deﬁnition of CNV on chromosome 22 at marker
AGAT055Z (25 cM on the Marshﬁeld genetic map).
This ﬁnding overlaps with a previous report of linkage
(Seddon et al. 2003) and is near the TIMP3 gene (Weber
et al. 1994), which, when mutated, can cause Sorsby
fundus dystrophy. We also observed suggestive evidence
for linkage with the CNV phenotype on chromosomes
9 and 19. The chromosome 9 signal overlaps with two
previously reported ﬁndings (Weeks et al. 2001; Ma-
jewski et al. 2003). Using the broader AMD classiﬁca-
tion and GA phenotypes, we observed the strongest ev-
idence for linkage ( ) on chromosome 5. ThisLOD 1 2.0
peak is 25 cM telomeric to a recent linkage ﬁnding
(Schick et al. 2003).
Finally, our study also replicates another promising
linkage ﬁnding. With the broad AMD phenotype, we ob-
served suggestive evidence of linkage on chromosome 1,
at marker GATA51H01 ( ; ; 205LODp 1.55 Pp .004
cM). Linkage in this region has been reported in three
other affected relative pair studies (Weeks et al. 2001;
Majewski et al. 2003; Seddon et al. 2003) and in the study
of a single large pedigree with AMD (Klein et al. 1998).
Multipoint Analyses
Overall, our multipoint analyses (ﬁgs. 2 and 3; table 3)
identiﬁed a subset of the regions observed in the single-
point analysis. With the AMD and GA traits, multipoint
analysis modestly increased the evidence for linkage on
chromosome 1 ( ; ) near the peakLODp 2.13 Pp .0009
that was reported in other affected relative pair studies
(Weeks et al. 2001; Majewski et al. 2003; Seddon et al.
2003); it also increased the evidence for linkage on chro-
mosome 5 ( ; ) near the linkageLODp 2.55 Pp .0003
ﬁnding of Schick et al. (2003). In contrast, evidence for
linkage was weakened for the chromosome 9 and 22 ﬁnd-
ings. Although multipoint analysis is theoretically more
powerful, it is also more sensitive to errors in genotyping
and in genetic map speciﬁcation (Abecasis et al. 2001a;
Sullivan et al. 2003). Thus, although it is likely that some
of the unreplicated single-point linkage signals may be
false positives, it is possible that other signals were lost
due to genotyping errors or genetic map inaccuracies.
Simulation Results (Single-Point Analysis)
Overall, none of our individual linkage signals reached
genomewide signiﬁcance. For example, our most signif-
icant ﬁnding, a LOD score of 2.55 for the broad CNV
phenotype, was observed by chance in 13/100 simulated
genomes (table 4). The result is similar when we consider
the restricted CNV phenotype, for which a LOD score
of 2.59 was observed in 9/100 replicates. However, our
simulations suggest that at least some of our observed
linkage signals are likely to be real. For example,
whereas we observed 7 linkage signals for the CNV phe-
notype at a LOD score threshold of 1.55, only 2.5 such
signals are expected to occur by chance and 0/100 (none)
simulated data sets showed as many signals. This is con-
sistent with an oligogenic basis for AMD. That is, mul-
tiple loci are likely to be involved, and, although the
effect of each locus is small (so that larger samples are
required to achieve genomewide signiﬁcance), they result
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Figure 2 Multipoint nonparametric linkage analysis at equally spaced locations throughout the genome by use of the NPLALL statistics
(Whittemore and Halpern 1994). LOD scores (Kong and Cox 1997) for six disease subtypes are plotted at 1-cM intervals. The solid lines
denote the strict trait deﬁnition, and the dotted lines denote the broad trait deﬁnition. The blue line indicates AMD, the red line indicates GA,
and the green line indicates CNV.
in an excess of modest linkage peaks in studies such as
this one. The results were less striking for the B-AMD
analysis (5 peaks observed, 2.70 expected) and GA phe-
notypes (3 peaks observed, 2.53 expected; table 4).
When all three phenotype classiﬁcations are considered,
we observed a total of 14 linkage signals at a LOD score
threshold of 1.52, compared with 6.87 expected to occur
by chance. Only one of our replicate data sets included
14 signals by chance. Results were similar for the
stricter disease deﬁnition (not shown).
Simulation Results (Multipoint Analysis)
Because of computational constraints, we only gen-
erated 25 simulated genomes for multipoint analysis. As
in the single-point analysis, no individual peak appears
to reach genomewide signiﬁcance, and peaks with sim-
ilar or higher LOD scores were observed in some of the
simulated genomes. For example, the most signiﬁcant
LOD score in our original multipoint analysis was a
observed on chromosome 5 for the broadLODp 2.55
GA phenotype. For this phenotype, we observed a sim-
ilar or higher LOD score on 3/25 simulated genomes.
When we considered all six (three broad and three re-
stricted) phenotype classiﬁcations, a similar or higher
LOD score was observed on 11/25 simulated genomes.
Nevertheless, for all the LOD score thresholds and phe-
notype classiﬁcations we considered, the original data
set shows more linkage signals than the average simu-
lated genome. For example, at a LOD score threshold
of 1.64 we observed linkage signals on three chromo-
somes for the broad CNV phenotype—an event that
occurred in only 2/25 simulated genomes. At the same
LOD score threshold, we observed evidence for linkage
in ﬁve autosomes when all phenotypes were consid-
ered—an event that occurred in 9/25 genomes.
Evidence for Interaction
We found only weak evidence for interaction between
different linkage signals. The correlation between the sig-
nals on chromosomes 9 and 22 was ( ,rp .34 Pp .04
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Figure 3 Multipoint nonparametric linkage analysis at equally spaced locations throughout the genome by use of the NPL-ALL statistics
(Whittemore and Halpern 1994). LOD scores (Kong and Cox 1997) for six disease subtypes are plotted at 1-cM intervals. The solid lines
denote the strict trait deﬁnition, and the dotted lines denote the broad trait deﬁnition. The blue lines indicate AMD, the red lines indicate GA,
and the green lines indicate CNV. The multipoint LOD score plots for four chromosomes of interest (1, 5, 9, and 22) are shown.
but not signiﬁcant after adjusting for multiple testing).We
also found that the mean age at diagnosis was typically
lower in families showing evidence of linkage to chro-
mosome 1 and 2 (correlation and , re-rp .52 rp .34
spectively; and ), but again this result isPp .01 Pp .03
not signiﬁcant after adjustments for multiple testing.
HEMICENTIN-1.—The Gln5345Arg change in HEM-
ICENTIN-1 was not detected in any of the 620 (274
R-AMD and 346 other) affected individuals and 237
unaffected controls. Moreover, no sequence variation
was identiﬁed in exon 104 in any of the DNA samples
examined.
Discussion
We report here the results of a nonparametric linkage
analysis of the ﬁrst high-resolution genomewide scan for
AMD susceptibility loci. Our AMD population included
affected relative pairs that were enriched for late-stage
disease forms (GA and/or CNV); this allowed us to search
for susceptibility loci for the more severe AMD pheno-
types. Our approach is biased toward disease phenotypes
with higher genetic susceptibility load. It is unclear if GA
and CNV are separate disease entities or part of a disease
spectrum. Some individuals can be affected by only one
form of late-stage disease, whereas others can be affected
by both, suggesting that the two late-stage forms may be
distinct yet share some common genetic predisposition.
Our results provide stronger evidence of genetic linkage
when analyses are focused on a subset of individuals with
one of the late-stage phenotypes. Overall, we identiﬁed
severalmodest linkage signals; both single- andmultipoint
analyses provided indications of linkage on chromosomes
1q, 2p, 5p, 9q, and 22q.
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Table 3
Peak Multipoint LOD Scores
Chromosome
and Disease Trait Nearest Marker
Marker
Location (cM)
Position
(cM) LOD
Interval
(cM) Peak P Value
1:
AMD BROAD GAT004 236 235 1.51 (208–239) .004
AMD RESTR GAT004 236 236 2.13 (223–244) .0009
GA BROAD GATA4H09 240 238 1.95 (233–243) .0014
GA RESTR GATA4H09 240 240 1.98 (234–245) .0013
2:
CNV BROAD GATA72G11N 10 10 1.96 (4–18) .0013
CNV RESTR GATA72G11N 10 10 1.76 (4–17) .002
CNV RESTR AGAT021 266 267 1.63 (262–267) .003
5:
AMD BROAD GATA12A08 40 42 1.72 (38–56) .002
GA BROAD GATA63C02 50 50 2.55 (39–91) .0003
GA RESTR GATA63C02 50 50 2.13 (40–89) .0009
9:
CNV BROAD GGAA22E01 111 111 1.64 (99–112) .003
CNV RESTR GGAA22E01 111 111 1.65 (103–112) .003
22:
CNV BROAD AGAT055Z 25 25 1.87 (19–31) .002
CNV RESTR AGAT055Z 25 25 2.03 (19–31) .0011
NOTE.—Nonparametric linkage analysis was performed using the SALL statistic (Whittemore andHalpern
1994). The table lists all linkage peaks with a LOD score (Kong and Cox 1997) 11.5 in multipoint analyses.
For each peak, the LOD score cM location and P values are listed (according to the Marshﬁeld genetic
map), as well as the interval in which the LOD score is 11.0.
Four groups have recently published whole genome
scan linkage results; however, so far only suggestive ev-
idence has been obtained for AMD susceptibility loci
(Weeks et al. 2001; Majewski et al. 2003; Schick et al.
2003; Seddon et al. 2003). Identiﬁcation of numerous
putative chromosomal locations in these studies is con-
sistent with the underlying genetic complexity of AMD
pathogenesis. Yet, it is most encouraging that, in spite
of differences in patient population and diversemethods
of analysis, many of our linkage signals were also de-
tected in at least one of the previous reports. The val-
idation of these loci by independent studies argues in
favor of these loci harboring genes that contribute to
the development of AMD.
One of the signals we identiﬁed on 1q31 (with a mul-
tipoint LOD score p 2.13, using the R-AMD classiﬁ-
cation) was originally described by linkage analysis in
a large AMD family (Klein et al. 1998) and has now
been reported in three (Weeks et al. 2001; Majewski et
al. 2003; Seddon et al. 2003) of four published affected
relative pair studies for AMD. The fourth study (Schick
et al. 2003) used a population with both mild and severe
forms of disease and observed weak evidence for link-
age. Consistent with Klein et al. (1998), most of this
linkage signal in our study appears to be contributed
by families with GA (correlation between per-family
LOD scores for GA and AMD at this position is 0.56;
). Thus, it appears that the chromosome 1qPp .006
locus is involved in AMD susceptibility; however, the
extent of its involvement in disease pathogenesis is un-
clear at this stage. The estimates for the percentage of
families linked to chromosome 1q varies from 7% to
40% (Weeks et al. 2001; Majewski et al. 2003). In our
study, 149% of the families in each disease classiﬁcation
provide evidence for linkage of AMD susceptibility to
chromosome 1q ( ).LOD 1 0
Recently, Schultz et al. (2003) suggested that a
Gln5345Arg variant in exon 104 of HEMICENTIN-1
is responsible for ARMD1 locus. We did not detect this
variant, or any other sequence change, in exon 104 of
HEMICENTIN-1 either in 274 individuals in the R-
AMD group, which exhibited the highest LOD score
for this region, or in 346 additional patients with AMD.
Our results suggest that variation(s) in another suscep-
tibility gene at 1q, and not the Gln5345Arg change in
HEMICENTIN-1, contribute to the disease in our
AMD cohort. Our linkage peak is telomeric of HEMI-
CENTIN-1, and, in our view, the results of Schultz et
al. (2003) are compatible with the hypothesis that
Gln5345Arg variant is a marker for the disease hap-
lotype in their large pedigree but is not itself causal. We
believe that further detailed studies of the candidate
region on chromosome 1q are warranted. The region
encompasses many other interesting candidate genes,
including phosducin, two genes involved in the protein-
ubiquitination pathway (ubiquitin carboxyl-terminal
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Table 4
Summary of Simulation Results (Single-Point Analyses) Using the Broad Phenotype Deﬁnition
Trait and
Threshold
Observed
Peak (x)
Expected
False Positive
Proportion of
Replicates
Where X  x Observed Signal
AMD-B:
2.08 1 .70 54/100 GATA12A08, Chr 5, 40 cM
1.77 2 1.51 47/100 TTTA001, Chr 7, 125 cM
1.63 3 2.21 42/100 GATA146H09, Chr 19, 11 cM
1.55 4 2.62 32/100 GATA51H01, Chr 1, 205 cM
1.53 5 2.70 17/100 GATA70B08, Chr 21, 58 cM
GA-B:
1.77 1 1.11 65/100 GATA7C06, Chr 5, 45 cM
1.53 2 2.46 73/100 GATA25A04, Chr 17, 62 cM
1.52 3 2.53 45/100 GATA90G11, Chr 14, 51 cM
CNV-B:
2.55 1 .13 13/100 AGAT055Z, Chr 22, 25 cM
2.12 2 .58 16/100 ATC6A06N, Chr 17, 67 cM
1.97 3 .95 7/100 AAT255, Chr 5, 130 cM
1.91 5 1.13 0/100 AGAT142, Chr 9, 34 cM
TTTA062, Chr X, 181 cM
1.84 6 1.40 0/100 AGAT021, Chr 2, 266 cM
1.71 7 1.96 0/100 GATA48E02, Chr 11, 21 cM
1.55 8 2.80 0/100 GATA151F03N, Chr 15, 60 cM
hydrolase L5 and HSPC150), the regulator of fas-in-
duced apoptosis, and several genes for immune mod-
ulatory proteins (e.g., interleukin 10, interferon regu-
latory factor 6, complement related molecules, andTNF
receptor-associated factor 5).
In multipoint analyses, our most striking linkage ﬁnd-
ing in families with GA is on chromosome 5p (50 cM
on the Marshﬁeld genetic map), close to another pre-
viously reported linkage signal (Schick et al. 2003). In-
teresting candidate genes in this region include caspase
recruitment domain family member 6 (CARD6) and
genes for several immune-related molecules (gp130-like
monocyte receptor, interleukin 6 signal transducer, com-
plement-c1q tumor necrosis factor-related protein 3,
and leukemia inhibitory factor receptor).
Our data support the linkage peak obtained by Ma-
jewski et al. (2003) on chromosome 9q, which was their
most robust peak, observed in both their initial and
expanded sample and by both parametric and non-
parametric linkage analysis. It is interesting to note that
Weeks et al. (2001) reported a possible locus at a lo-
cation ∼40 cM away; but their evidence was weakened
after the number of affected sib pairs analyzed was in-
creased. Our evidence for linkage to chromosome 9 was
strengthened when the analysis was performed using
only CNV sib pairs. This region contains genes for fork-
head box E1 (FOXE1) and ATP-binding cassette, sub-
family A (ABC1); the latter is associated with Tangier
disease and familial high-density lipoprotein deﬁciency.
In addition to the three linkage signals (chromosome
1q, 5p, and 9q) that we consider signiﬁcant, we found
evidence for a susceptibility locus on chromosome 22
near TIMP3, a gene mutated in Sorsby fundus dystrophy
(Weber et al. 1994), when we focused our analysis on
the subset of patients with CNV. Most patients with
Sorsby fundus dystrophy develop night blindness in their
20s and subfoveal choroidal neovascularization by 40
years of age. In contrast, the average age at diagnosis for
our CNV patients is 170 years (see table 1). Although
no TIMP3 association was evident by the analysis of 188
patients with AMD (Stone et al. 2001), we speculate that
sequence variations in TIMP3 may lead to a later-onset
neovascularization phenotype, possibly in association
with other AMD susceptibility loci and environmental
factors. It will therefore be of interest to perform TIMP3
association study in patients with CNV.Other potentially
interesting candidates on chromosome 22 include the
genes for heat shock 27 protein 3, leukemia inhibitory
factor (LIF), calcineurin, ubiquinol-cytochrome c reduc-
tase complex, complement-c1q tumor necrosis factor-re-
lated protein 6, caspase recruitment domain family mem-
ber 10, and several APOB-editing enzymes. Recently,
both mRNA and protein for APOB were found to be
expressed in normal adult RPE, and APOB was detected
in drusen and basal deposits, suggesting a link between
APOB and development of cholesterol-enriched lesions
in AMD (Malek et al. 2003).
We did not ﬁnd signiﬁcant evidence for other previ-
ously suggested AMD loci in our analysis (Weeks et al.
2001; Majewski et al. 2003; Schick et al. 2003; Seddon
et al. 2003). Prominent among these is the putative locus
on chromosome 10q26, which was reported in three
studies; although the evidence was weak in two reports
(Weeks et al. 2001; Seddon et al. 2003), Majewski et
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al. (2003) obtained a HLOD score of 3 in nuclear fam-
ilies when parametric analysis with high penetrance was
performed. Our nonparametric analysis did not dem-
onstrate any evidence for an AMD susceptibility locus
on chromosome 10.
In summary, this nonparametric linkage analysis of a
high-resolution (5-cM) whole genome scan provides
support for several previously reported chromosomal
locations of AMD loci. In addition, we suggest new
genetic loci (e.g., on chromosome 2) that may predis-
pose individuals to late-stage AMD (GA or CNV). We
have also found weak but interesting evidence for in-
teraction between different susceptibility loci. When
searching for genetic loci involved in complex diseases,
crossvalidation of genetic data by different groups is
important, since it is not easy for one group to obtain
statistically signiﬁcant evidence of linkage. The consis-
tency between our results and previous studies suggests
that genetic studies should be successful in identifying
the molecular basis of AMD, thereby assisting in di-
agnosis, as well as in the design of novel prevention and
therapeutic strategies.
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